Rachel M Ostroff

Summary

Publications

  1. ncbi Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool
    Rachel M Ostroff
    Clinical Research, SomaLogic Inc, Boulder, Colorado, United States of America
    PLoS ONE 7:e46091. 2012
  2. ncbi Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer
    Rachel M Ostroff
    SomaLogic, Boulder, Colorado, United States of America
    PLoS ONE 5:e15003. 2010
  3. ncbi Protein signature of lung cancer tissues
    Michael R Mehan
    SomaLogic, Inc, Boulder, Colorado, United States of America
    PLoS ONE 7:e35157. 2012
  4. ncbi Aptamer-based multiplexed proteomic technology for biomarker discovery
    Larry Gold
    SomaLogic, Boulder, Colorado, USA
    PLoS ONE 5:e15004. 2010

Collaborators

Detail Information

Publications4

  1. ncbi Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool
    Rachel M Ostroff
    Clinical Research, SomaLogic Inc, Boulder, Colorado, United States of America
    PLoS ONE 7:e46091. 2012
    ..To improve surveillance and detection of MM in the high-risk population, we completed a series of clinical studies to develop a noninvasive test for early detection...
  2. ncbi Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer
    Rachel M Ostroff
    SomaLogic, Boulder, Colorado, United States of America
    PLoS ONE 5:e15003. 2010
    ..Here we present a comprehensive clinical biomarker study of lung cancer and the first large-scale clinical application of a new aptamer-based proteomic technology to discover blood protein biomarkers in disease...
  3. ncbi Protein signature of lung cancer tissues
    Michael R Mehan
    SomaLogic, Inc, Boulder, Colorado, United States of America
    PLoS ONE 7:e35157. 2012
    ..The combined results from tissue and serum present the most extensive view to date of the complex changes in NSCLC protein expression and provide important implications for diagnosis and treatment...
  4. ncbi Aptamer-based multiplexed proteomic technology for biomarker discovery
    Larry Gold
    SomaLogic, Boulder, Colorado, USA
    PLoS ONE 5:e15004. 2010
    ..The interrogation of proteomes ("proteomics") in a highly multiplexed and efficient manner remains a coveted and challenging goal in biology and medicine...